Although retinoic acid receptor alpha (RARα) agonists induce the maturation of t(15;17) acute promyelocytic leukemia (APL) cells, drug treatment also selects leukemic blasts expressing PML-RARα fusion proteins with mutated ligand-binding domains that no longer respond to all-trans retinoic acid (ATRA). Here we report a novel RARα-independent signaling pathway that induces maturation of both ATRA-sensitive and ATRA-resistant APL NB4 cells, and does not invoke the ligand-induced alteration of PML-RARα signaling, stability or compartmentalization. This response involves a cross-talk between RXR agonists and protein kinase A signaling. Our results indicate the existence of a separate RXR-dependent maturation pathway that can be activated in the absence of known ligands for RXR heterodimerization partners.
Introduction
Acute promyelocytic leukemia (APL), originating from the generation of a retinoic acid receptor fusion protein (PML-RARα) due to a t(15;17) chromosomal translocation (Rowley et al., 1977; Borrow et al., 1990; de Thé et al., 1990 de Thé et al., , 1991 Goddard et al., 1991; Kakizuka et al., 1991; Kastner et al., 1992) , is the prototype of a cancer treated by differentiation therapy using all-trans retinoic acid (ATRA; Huang et al., 1988; Castaigne et al., 1990; Fenaux et al., 1997) . Although the mechanism triggering APL cell maturation remains unclear, it is generally admitted that the formation of PML-RARα causes a differentiation block that can be relieved by RARα agonists (reviewed by Slack and Gallagher, 1999) . PML-RARα acts as a ligand-responsive transcription regulator, which forms heterodimers with RXRs (Perez et al., 1993) and interacts with nuclear receptor coregulators. It has been proposed that increased corepressor binding efficiency to PML-RARα causally relates to the differentiation block of APL blasts [Hong et al., 1997; Grignani et al., 1998; Guidez et al., 1998; He et al., 1998; Lin et al., 1998 ; the structural and functional implications of nuclear receptor/ coregulator interactions have been reviewed by Moras and Gronemeyer (1998) and Xu et al. (1999) ]. In vitro studies (Kizaki et al., 1996; Kitamura et al., 1997; Shao et al., 1997) and clinical observations (Imaizumi et al., 1998) have shown that mutations in PML-RARα at the ligandbinding domain abrogate ATRA-induced APL cell maturation. At present it is unclear whether ATRA simply de-represses a PML-dependent or activates an RARα-dependent signaling pathway, and whether the ATRA-induced association of PML-RARα with nuclear bodies correlates with, or is required for, blast cell maturation. In fact, in vivo RARα is apparently not required for granulocyte differentiation, as RARα -/-mice have a normal granulocyte compartment (Labrecque et al., 1998) . This suggests that in vivo RARα is either not required for normal granulopoiesis or that alternative signaling pathways exist. To investigate the possibility of inducing APL cell maturation by an RARα-independent signaling pathway, we analyzed comparatively the cellular consequences of RAR (retinoid) and RXR ('rexinoid'; Mukherjee et al., 1997) ligands on triggering maturation of the prototypic t(15;17) APL NB4 cell line (Lanotte et al., 1991) and ATRA-resistant NB4 subclones (Duprez et al., 1992; Ruchaud et al., 1994) .
Results
Differential actions of RAR-and RXR-specific agonists on NB4 cells: cross-talk between rexinoid and protein kinase A signaling induces cell maturation As reported previously (Chen et al., 1996) , all RARα agonists (ATRA, 9-cis retinoic acid, BMS753; the activities of all the ligands discussed are summarized in Table I ) induce maturation of NB4 cells (Figure 1A , top; Figure 1B , lanes 7 and 12; Figure 1C , lanes 5 and 9). In keeping with the critical role of PML-RARα and/or the resident non-affected RARα allele, neither RARβ-(BMS641) nor RARβγ-(BMS961) selective retinoids induced differentiation as assessed by morphological criteria ( Figure 1A , top), NBT reduction ( Figure 1B , lanes 18 and 20) and CD11c integrin expression ( Figure 1C, lanes 13 and 15) . That RAR pan-agonists also induce NB4 maturation through RARα activation is demonstrated by the observations that the RARα-selective antagonist BMS614 dramatically decreased the maturation induced by 9-cis retinoic acid (9-cis RA; Figure 1B , lane 8; Figure 1C , lane 6; similar data were obtained for ATRA, not shown). As expected, the RARα agonist BMS753-induced differentiation was abrogated by BMS614 or the RAR panantagonist BMS009 ( Figure 1B , lanes 13 and 14; Figure 1C , lane 10). In contrast to RAR agonists, RXR 
The transcriptional activities of synthetic retinoids were determined for the AF-2 functions of RARα, β, γ and RXRα using reporter cells ( Figure 3A ; Chen et al., 1995) . RXRα homodimer activity on a DR1-tk-CAT or RARα-RXRα heterodimer activity on a DR5-tk-CAT reporter were assessed by transient RXR transfections. 'ϩ', agonist; '(ϩ)', weak agonist; '-', antagonist; '0', no activity; 'nd', not determined.
agonists (SR11237; Lehmann et al., 1992) alone were completely inactive ( Figure 1A , top; Figure 1B , lane 23; Figure 1C , lane 17; Kitamura et al., 1997) . Surprisingly, however, the SR11237 rexinoid agonist, which is devoid of any RAR activity (Lehmann et al., 1992; Chen et al., 1996) , induced full maturation of NB4 cells in the presence of the protein kinase A (PKA) agonist 8CPT-cAMP, which on its own did not exhibit any differentiating activity. Morphological changes, CD11c integrin expression and NBT reduction assays all demonstrated that the RXR-PKA cross-talk induced bona fide granulocytic maturation of NB4 cells as does ATRA (Figure 1A , lower; Figure 1B , lane 24; Figure 1C , lane 18). Similar results were obtained with other rexinoid agonists (BMS749; see below). Importantly, neither RARα-selective (BMS614) nor RAR pan-antagonists (BMS009; identical results were obtained with other RAR panantagonists, such as BMS493, data not shown) affected significantly the RXR-PKA synergism for NB4 maturation, irrespective of whether 9-cis RA or SR11237 was used as RXR agonist (Figure 1B and C) . This excludes any contribution of serum-borne traces of retinoic acid, as well as unrecognized weak RAR agonist cross-reactivity of SR11237, since RAR-agonist-induced differentiation is inhibited efficiently by these antagonists (see above). Excess of the RXR antagonist HX531 (Vivat et al., 1997) largely decreased the rexinoid-PKA agonist-induced differentiation of NB4 cells, as shown by NBT assays ( Figure 1B) , as well as morphological criteria and CD11c expression (data not shown). Note that the incomplete inhibition of differentiation by HX531 is most likely due to its weak binding affinity (compare also Vivat et al., 1997) . As expected, no synergy was observed between the RXR antagonist and 8CPT-cAMP ( Figure 1B) .
These data indicate the existence of a novel NB4 cell-differentiation pathway that requires agonist-bound, transcriptionally competent RXR and, in contrast to the classical ATRA-induced pathway, is operative in the presence of RAR antagonists.
Nuclear body disintegration and PML-RARα stability are not affected during rexinoid-PKA agonist-induced differentiation Although RXR-PKA synergy induces NB4 cell maturation, several cellular and biochemical events, previously considered to be key features of APL cell differentiation, are not observed. In particular, this concerns the reorganization of nuclear structures and the stability of the PML-RARα protein.
It is well documented that ATRA exposure of APL blasts or NB4 cells reverses the destabilization of specific nuclear structures, referred to as nuclear bodies or PODs (Hodges et al., 1998) , caused by the PML-dependent targeting of PML-RARα to these structures (Dyck et al., 1994; Koken et al., 1994 Koken et al., , 1997 Weis et al., 1994; Duprez et al., 1996a) . Notably, no reorganization of nuclear bodies was seen when NB4 cell maturation was induced by rexinoid (SR11237)-PKA cross-talk ( Figure 2A ). The absence of nuclear body reorganization was confirmed using antibodies directed against PML (Figure 2A ) or SP100 (data not shown), thus excluding the possibility that a subset of nuclear bodies harboring PML-RARα could exist that would not reorganize upon maturation. Concomitant with the reformation of nuclear bodies, ATRA induces PML-RARα degradation (Duprez et al., 1996b; Raelson et al., 1996; Yoshida et al., 1996) . In keeping with the persistence of destabilized nuclear bodies, exposure of NB4 cells to SR11237 plus 8CPT-cAMP did not affect PML-RARα stability under conditions in which efficient maturation was observed ( Figure 2B ). Taken together, the above results indicate that the PML-RARα fusion-induced differentiation block in t(15;17) APL cells can be relieved by rexinoid-PKA cross-talk without affecting PML-RARα stability or reversing its effects on nuclear body integrity.
Evidence for (PML-)RAR-RXR heterodimerindependent rexinoid signaling
To provide additional evidence that it is not the (PML-)RAR-RXR heterodimer whose PKA cross-talk induces differentiation, we took advantage of the recently discovered retinoid, BMS749. This retinoid has the rather exceptional characteristics that it acts as a strong RXR AF-2 (GAL-RXRα; Figure 3A ) and RXR homodimer ( Figure 3B , lane 3) agonist on 17mer- and DR1-based reporters, respectively, whereas it is a pan-antagonist for RAR AF-2s ( Figure 3A) , and almost inactive with RAR-RXR heterodimers on a DR5-based reporter ( Figure 3B , lane 7). Despite being virtually inactive on its own, BMS749 did not inhibit, but rather synergized with, ATRA-induced transactivation of DR5 reporters ( Figure 3B , lane 8). In keeping with its inefficiency in activating the RAR-RXR heterodimer, BMS749 alone did not exert any differential effect on NB4 cells ( Figure 3C ). However, in the presence of 8CPT-cAMP this retinoid induced maturation with a potency similar to 9-cis RA ( Figure 3C ). Importantly, this activity was also seen in the presence of a transactivation-incompetent RARα, as it could not be inhibited by RARα-selective (BMS614) or pan-antagonists ( Figure 3C ; data not shown). (C) Flow-cytometry analysis of CD11c integrin expression following treatment of NB4 cells by retinoids and cAMP (after 48 h). Pan-agonists (ATRA, 9-cis RA) and RARα agonists (BMS753), but not RARβ (BMS641) and RARβγ (BMS961) agonists, induce NB4 cell maturation. On its own the RXR pan-agonist SR11237 failed to trigger NB4 cell maturation. However, consistent with an RXR-ligand-dependent signaling, co-treatment with SR11237 and cAMP induces maturation of NB4 cells through a pathway that is not inhibited by the RAR antagonists BMS614 or BMS009. No evidence for the implication of RXR heterodimers with TR, VDR and PPAR in RXR-PKA cross-talk RXR is a promiscuous heterodimerization partner for a great number of nuclear receptors (Gronemeyer and Laudet, 1995; Mangelsdorf et al., 1995; Chambon, 1996) and NB4 differentiation could potentially be mediated by heterodimers other than RAR-RXR. To this end we tested whether thyroid hormone, vitamin D3 or PPAR agonists in the presence of either the RXR agonist SR11237 or 8CPT-cAMP would induce the differentiation of NB4 cells. However, combinations of TR or PPAR pan-or isotype-selective (provided by Bristol-Myers Squibb) agonists with SR11237 or 8CPT-cAMP did not induce any maturation (data not shown). Only vitamin D3, which was inactive on its own or in the presence of SR11237, cross-talked at a µM concentration with 8CPT-cAMP to produce a moderate granulocytic maturation (according to NBT staining), which was~20% of the effect exerted by SR11237 in the presence of the PKA agonist. The vitamin D3-PKA effect was additive to that exerted by rexinoid-PKA synergism, suggesting that the two cross-talks operate independently of each other. As none of the above heterodimers efficiently induced NB4 cell differentiation in response to the cognate ligand of the RXR partner when co-exposed to 8CPT-cAMP, it is unlikely that the rexinoid acted through one of the above heterodimers. This is further supported by the apparently distinct gene programs initiated by vitamin D3 and the rexinoid-PKA agonist synergy (see below and Figure 4) . No cross-talk between the PKA pathway was seen with rexinoid antagonists (Figure 1B) , such as the RXR-selective pan-antagonist HX531 (Vivat et al., 1997) , indicating that synergism requires RXRs to be in a transcription-activating conformation.
ATRA and rexinoid-PKA agonist-induced signaling pathways trigger distinct gene programs The above data suggest that two distinct pathways exist for NB4 cells to undergo maturation. One involves (PML-)RARα-RXR heterodimers and can be activated by RARα agonists, whereas the second does not involve such heterodimers and depends on the cross-talk between RXR and PKA agonists. Monitoring cytokine signaling of NB4 cells by multiplex RNase protection assays demonstrated that the two pathways do indeed regulate different, albeit overlapping, gene programs. Most remarkably, the expression of granulocyte colony stimulating factor (G-CSF), which is weakly induced by the PKA agonist 8CPT-cAMP ( Figure 4A , lane 9), is boosted dramatically by SR11237 (lane 15), even though SR11237 on its own does not affect G-CSF expression (lanes 10-12). The synergy factor was Ͼ50-fold, leading to a huge stimulation of G-CSF gene expression, which was undetectable in the non-induced state. Notably, ATRA was incapable of stimulating G-CSF expression ( Figure  4A, lanes 1-3) , but induced the expression of macrophage colony stimulating factor (M-CSF; lane 3) and the C-X-C chemokine interferon-inducible protein 10 (IP10; Figure 4B , lane 3), which were not seen with SR11237 and/or 8CPT-cAMP. GM-CSF expression was triggered selectively by the RXR-PKA cross-talk ( Figure 4A , lane 15) and SR11237 further stimulated 8CPT-cAMP induction of the expression of interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP1) and the C-C chemokines macrophage inflammatory proteins MIP1α and MIP1β ( Figure 4B, lanes 9 and 15) . IL-8 and MCP1 expression was also induced by ATRA ( Figure 4B, lanes 2  and 3) . Notably, some cytokines were induced by SR11237 on its own, as the c-kit ligand stem cell factor (SCF), IL-8 and MCP1 ( Figure 4A and B, lanes 11 and 12) . The only other tested condition leading to SCF induction was exposure to vitamin D3 ( Figure 4A , lanes 5 and 6), which also induced IL-8 expression ( Figure 4B , lanes 5 and 6). The C-C cytokine RANTES, which is constitutively expressed in NB4 cells, is inhibited by the PKA agonist. This inhibition was compensated for by co-exposure to SR11237, leading only to a transient decrease at 24 h ( Figure 4B , compare lanes 7-9 with lanes 13-15).
RXR-PKA cross-talk induces maturation of retinoid-resistant cells
That two distinct pathways can induce NB4 cell differentiation prompted us to test whether ATRA-resistant cells would still respond to the RXR-PKA cross-talk. Indeed, NB4-R2 cells (Duprez et al., 1992 (Duprez et al., , 2000 Ruchaud et al., 1994) , which are resistant to ATRA due to the mutation of Gln 411 to an in-phase stop codon in the ligand- Reporter cell assays; the RAR and RXR AF-2 agonistic and antagonistic activities of BMS749 are displayed as a false color illustration of the luciferase activity emanating after retinoid induction (from 1 nM, '-9' to 1 µM, '-6') from 96-well plates containing equal numbers of cells . Monitoring and quantitation was carried out using a photon-counting camera. (n), Signals in the presence of the retinoid (agonist activity; '-' indicates the signal for the vehicle alone); (m), signals in the presence of both 10 nM ATRA ('-', only ATRA) and increasing amounts of the retinoid (antagonistic activity, if the ATRA-induced signal decreases). Note that the RXRα reporter cell line also contains the inactive dnRXRα∆AB, which lacks both AF-1 and AF-2, to sequester endogenous RARs that silence RXR in the absence of RAR agonists (Vivat et al., 1997) . (B) Transient transactivation of RXRα homodimers on a DR1 reporter in the presence of BMS749 (relative to 0.1 µM 9-cis RA, standardized to 100) and of RARα-RXRα heterodimers (relative to 10 nM ATRA, standardized to 100). The small DR5 activation in lane 7 may originate from the weak interaction of RXR homodimers with DR5 elements (Mader et al., 1993) . (C) BMS749 is a highly potent partner of PKA signaling to trigger NB4 cell maturation. Morphological and histochemical features of NB4 cells treated with BMS749, with or without 8-CPT-cAMP as indicated. Comparative analysis of the synergistic action of cAMP and 9-cis RA or BMS749 to elicit NBT response and CD11c expression in NB4 cells is shown on the right. binding domain of PML-RARα ( Figure 5A ), ceased growth in the presence of SR11237 or BMS749 plus 8CPT-cAMP (note that NB4, but not NB4-R2, cells are growth inhibited by BMS753; data not shown) and underwent granulocytic maturation, as confirmed by morphological criteria, NBT reduction ( Figure 5B ) and CD11c integrin expression (data not shown). Note that nuclear bodies, which are disrupted in NB4-R2 cells (Duprez et al., 1996b) , did not reform under these conditions (data not shown). Moreover, the rexinoid-PKA cross-talk induced the same pattern of cytokine expression in NB4 and NB4-R2 cells, whereas ATRA was unable to induce IP10, MCP1 or M-CSF expression in the resistant cells, as it did in the parental NB4 cells (Figure 4 and data not shown). No differentiation of NB4-R2 was seen in the presence of the rexinoid or PKA agonists alone, or in the presence of ATRA or 9-cis RA ( Figure 5B ). It is worth noting that, in the presence of 8CPT-cAMP, BMS753 induced some differentiation of NB4-R2 cells (lane 15), suggesting that the non-modified RARα allele can synergize with PKA agonists to induce some markers of differen-tiation even in the absence of morphological cell alterations ( Figure 5B, top) .
Discussion

RXR-PKA cross-talk constitutes a novel signaling pathway
Several arguments support our conclusion that NB4 cell differentiation can be achieved through two different signaling paradigms, i.e. either RARα agonists through (PML-)RARα-RXR heterodimers or through rexinoid-PKA agonist synergism. Owing to 'RXR subordination' the RAR-RXR heterodimer cannot respond to pure RXR agonists, such as SR11237, unless RAR is liganded (Lehmann et al., 1992; Kurokawa et al., 1994; Forman et al., 1995; Vivat et al., 1997) . In addition, BMS749, which is a RXR homodimer agonist and a RAR antagonist, was unable to activate RAR-RXR heterodimers efficiently on its own. However, together with the PKA agonist, but not on their own, both SR11237 and BMS749 efficiently induced NB4 cell differentiation. Note that we have Fig. 4 . Rexinoid-PKA cross-talk induces a cytokine expression program that differs from that induced by ATRA (A and B) . Modulation of cytokine expression in NB4 cells was assessed by multiplex RNase protection assays. Cells were exposed to the agents displayed at the top for 0, 24 and 48 h (subsequent lanes for each treatment). For comparison the effect of vitamin D3 (D3) was also studied. In (A) the intact probes run on the same gel are shown on the left (L32 and GAPDH are the invariant internal controls used for calibration) and the positions of the protected fragments are indicated. In (B) only the positions of the protected fragments are shown.
excluded the possibility that 8CPT-cAMP simply relieves 'RXR subordination' in RAR-RXR heterodimers, since we did not observe any SR11237-induced transactivation of a DR5-based reporter by co-expressed RAR and RXR in the presence of the PKA agonist (data not shown). The degradation of PML-RARα and the reorganization of PML nuclear bodies during ATRA treatment are regarded as key events during APL cell maturation. This work shows that reversion of the known PML-RARα-induced effects is not obligatory for APL cell maturation, thus further supporting the idea of a distinct pathway. Cytokine/ chemokine expression analysis confirms that SR11237 plus 8CPT-cAMP is not simply an alternative to induce the same gene program as RARα agonists. Transgenic mice expressing a dominant-negative RXR in myeloid cells exhibited maturation defects at the promyelocytic stage (Sunaga et al., 1997) indicating that RXR is not just a silent heterodimerization partner of RAR and plays an active transcriptional role either in hetero-or homodimers that is crucial for myelopoiesis. NB4 mutant cells, that do not respond to ATRA, do differentiate efficiently via the rexinoid-PKA pathway. Whether this PML-RAR-RXR heterodimer-independent pathway operates through synergy between the PKA pathway and RXR homodimers or via an as yet unidentified 'RXR permissive' heterodimer remains to be established. Also note that we use the terms 'rexinoid-PKA cross-talk' phenomenologically and do not distinguish between: (i) a direct action of one pathway on components of the other; and (ii) two separate signaling pathways whose actions complement each other with respect to cell differentiation.
Implications for APL therapy
Our data pave the way for alternative therapies for APL patients to inhibit the outgrowth of ATRA-resistant pools of leukemic blasts and eliminate such cells from relapsed (Duprez et al., 1992; Ruchaud et al., 1994) patients. The observations that: (i) ATRA augments the expression levels of the receptors for G-CSF (Tkatch, 1995) and GM-CSF (de Gentile et al., 1994) ; (ii) G-CSF and GM-CSF are superinduced by the PKA and rexinoid agonists ( Figure 4) ; and (iii) G-CSF combined with ATRA can increase granulocyte counts without leukemia regrowth in patients who developed neutropenia (Usuki et al., 1996) , suggest that a combination therapy using retinoid, rexinoid, which in human clinical trials did not manifest side-effects that are normally associated with retinoid therapy (Miller et al., 1997) , and PKA agonists (or drugs elevating cAMP levels) may provide a third therapeutic tool, in addition to combination therapies with ATRA plus chemotherapy and ATRA plus arsenic trioxide (Soignet et al., 1998; Lallemand-Breitenbach et al., 1999) .
Materials and methods
Ligands, cell lines, cell cultures and granulocytic maturation assays
Retinoids and PPARα and γ ligands were generously provided by BristolMyers Squibb. NB4 and NB4-R2 cells were cultured as described previously (Lanotte et al., 1991; Duprez et al., 1992; Ruchaud et al., 1994) . Essentially, cultures were established with log phase growing cells at a concentration (10 5 cells per ml) that allowed exponential growth of untreated control cultures over 3 days without medium replenishment. Retinoids (provided by Bristol-Myers Squibb; dissolved in ethanol as stock solution at 10 -3 M) and 8-CPT-cAMP (Sigma; dissolved in saline at 10 -2 M) were added at the indicated concentrations. Cultures were light-protected. Cell morphology was analyzed after MayGrünwald staining. A histological NBT reaction was carried out as described previously (Lanotte et al., 1991; Duprez et al., 1992) . Morphology analysis and the NBT reaction were performed 72 h after treatment. At least 300 cells were analyzed for each treated culture. The data given are typical of one experiment, each treatment was repeated at least three times. The expression of CD11c integrin was analyzed by direct immunofluorescence, essentially as described by Lanotte et al. (1991) . Briefly, after incubation (48 h), cells were washed in phosphatebuffered saline (PBS) and labeled with an anti-human CD11c fluorescein isothiocyanate (FITC) mouse monoclonal antibody (mAb; BectonDickinson). Cells were then washed twice in PBS and fixed in 1% paraformaldehyde/PBS solution. Cells were analyzed using a Coulter flow cytometer.
Cellular extracts and SDS-PAGE analysis
Cytoplasmic and nuclear protein extracts were as reported previously (Duprez et al., 1996a) . Protein extracts (5 µg) were loaded onto SDSpolyacrylamide gels, electrophoresed and blotted onto poly(vinylidene difluoride) (PVDF) membranes (Immobilon P; Millipore). Membranes were blocked with 5% non-fat milk in PBS pH 7.6, 0.1% Tween 20 (PBS-T), then incubated with a specific antiserum raised against human RARα [RPα(F)] in PBS-T/0.5% milk for 18 h at 4°C. Membranes were incubated with horseradish peroxidase (HRP)-coupled anti-rabbit antibody (Jackson Laboratories) for 30 min at 25°C. Each step was followed by three 10 min washes in PBS-T. Detection was performed as described in the ECL Kit (Amersham).
Confocal immunofluorescence analyses
For immunofluorescence studies, the cells were smeared onto histological glass slides using a cytocentrifuge (Cytospin, Shandon). After drying overnight, they were fixed in acetone at 4°C for 10 min and allowed to air dry for 20 min. The slides were incubated for 15 min with PBS and for 1 h with polyclonal rabbit antiserum raised against PML (Duprez et al., 1996a) or SP100 (generously provided by Drs M. Koken and H.de Thé) at a dilution of 1:500 in PBS. After three washes in PBS, the slides were incubated for 30 min with fluorescein-coupled anti-rabbit antibody (Biosys) at a dilution of 1:200 in PBS. After three washes in PBS, slides were mounted with 5 µl of fluorescent mounting medium (Dako). All incubations were carried out at room temperature. Preparations were examined by confocal laser scanning microscopy (MRC-600 Confocal Imaging System; Bio-Rad Microscience Ltd, Hertfordshire, UK), mounted on an optiphot II Nikon microscope. Images were collected using an oil immersion lens (60ϫ, NA I.4 plan apochromat). For fluorescein excitation an argon ion laser (Ion Laser Technology Inc., Salt Lake City, UT, USA) operating with the 488 nm line was used.
RNase protection assay
Total RNA was extracted with Trizol (Gibco-BRL). The ribonuclease protection assay was performed according to the supplier's instructions (Pharmingen, San Diego, CA, USA). Briefly, human cytokine 4 and 5 template sets (45034P; 45035P) were labeled with α-32 P uridine triphosphate. RNA (4 µg) and 6 ϫ 10 5 c.p.m. of labeled probes were used for hybridization. After RNase treatments, the protected probes were resolved on a 5% urea-polyacrylamide-bis-acrylamide gel.
Sequencing PML-RARα cDNA of NB4 and NB4-R2 cells Total RNA from NB4 and NB4-R2 cells was purified and PML-RARα-specific mRNA was isolated using Dynal magnetic beads (M-280 streptavidin) coupled to a biotinylated PML-RARα oligonucleotide (specific for the sequence at the recombination site). This mRNA preparation was used for RT-PCR with oligod(N)6 as the primer and AMV reverse transcriptase at 42°C for 60 min. One-twentieth of the RT reaction was used for PCR amplification with the primers R2L (CTG CCC CTG GAG ATG GAT GAT) and R2H (GCG GAG GGC GAG GGC TGT GTC) and the following conditions: 5 min at 95°C, cycle 1 min at 95°C, 2 min at 65°C, 1 min 30 s at 72°C and then 10 min at 72°C. The PCR product was gel isolated and cloned into the pCR™2.1 AT sequencing vector. Clones were selected and PCR-tested for the presence of the insert. Positive clones were selected, plasmids were purified from these clones and DNA was sequenced with SP6 and T7 primers using the Perkin-Elmer Big Dye kit and ABI 377 automatic sequencer.
